The effect of Cornus mas fruit extract consumption on lipid profile, glycemic indices, and leptin in postmenopausal women— A randomized clinical trial

2019 ◽  
Vol 33 (11) ◽  
pp. 2979-2988 ◽  
Author(s):  
Afsane Gholamrezayi ◽  
Naheed Aryaeian ◽  
Shahnaz Rimaz ◽  
Jamileh Abolghasemi ◽  
Soudabeh Fallah ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Lipid Profile ◽  
Postmenopausal Women ◽  
Randomized Clinical Trial ◽  
Fruit Extract ◽  
Cornus Mas ◽  
Glycemic Indices

The effect of Cornus mas extract consumption on bone biomarkers and inflammation in postmenopausal women: A randomized clinical trial

2021 ◽  
Author(s):  
Naheed Aryaeian ◽  
Fatemehsadat Amiri ◽  
Seyedeh Tayebeh Rahideh ◽  
Jamileh Abolghasemi ◽  
Shima Jazayeri ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Postmenopausal Women ◽  
Randomized Clinical Trial ◽  
Bone Biomarkers ◽  
Cornus Mas

The effect of ( Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: A double‐blind randomized clinical trial

2021 ◽  
Author(s):  
Zohreh Sadat Sangsefidi ◽  
Faezeh Yarhosseini ◽  
Mahdieh Hosseinzadeh ◽  
Alimohammad Ranjbar ◽  
Mohsen Akhondi‐Meybodi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Function ◽  
Fatty Liver ◽  
Randomized Clinical Trial ◽  
Fruit Extract ◽  
Double Blind ◽  
Nonalcoholic Fatty Liver ◽  
Cornus Mas

Multimedia education program and nutrition therapy improves HbA1c, weight, and lipid profile of patients with type 2 diabetes: a randomized clinical trial

Endocrine ◽  
2017 ◽  
Vol 58 (2) ◽  
pp. 236-245 ◽  
Author(s):  
Lubia Velázquez–López ◽  
Abril Violeta Muñoz-Torres ◽  
Patricia Medina-Bravo ◽  
Jenny Vilchis-Gil ◽  
Miguel Klϋnder-Klϋnder ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Lipid Profile ◽  
Randomized Clinical Trial ◽  
Education Program ◽  
Nutrition Therapy ◽  
Multimedia Education

Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.

1988 ◽  
Vol 6 (5) ◽  
pp. 825-831 ◽  
Author(s):  
J N Ingle ◽  
D I Twito ◽  
D J Schaid ◽  
S A Cullinan ◽  
J E Krook ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Side Effects ◽  
Postmenopausal Women ◽  
Randomized Clinical Trial ◽  
Statistical Significance ◽  
Metastatic Breast ◽  
Rank Test ◽  
Breast Cancer Patients

A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious than TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 TAM patients (42%) and 63 of 119 TAM plus FLU patients (53%) (one-sided P = .05). Time to disease progression distributions were better for TAM plus FLU (median, 350 days v 199 days), but the log rank test only approached statistical significance (one-sided P = .07). Duration of response and survival distributions were similar between the two treatment arms. Toxicities, in terms of androgenic side effects, were greater on the TAM plus FLU regimen. Fifty-two patients are evaluable for response with FLU following TAM and 21 (40%) have achieved a response. We conclude that the advantages in terms of response rate and time to progression observed with TAM plus FLU probably represent a biological effect, but are not of sufficient magnitude to justify the routine clinical use of this combination given the lack of survival advantage and side effects encountered.

Sign in / Sign up

Export Citation Format

Share Document